Medicare's GLP-1 Discount Program Leaves Some Patients Struggling

Jeff La Marca, a 68-year-old retired professor from Basking Ridge, New Jersey, found himself in a frustrating situation after his application for Medicare's new GLP-1 discount program was denied. La Marca had hoped that the recently launched pilot program would make the weight loss drug Zepbound financially accessible, as it offers a significant reduction in price from $750 to just $50 a month for eligible participants.

Despite his longstanding battle with obesity, morbidly so with a BMI of 42, and serious health issues including severe obstructive sleep apnea, La Marca's application was rejected. The notification didn’t clarify the reasons, but he suspects that his sleep apnea diagnosis disqualified him, leaving him without the necessary support for managing his weight effectively.

Approximately 5.9 million Medicare enrollees like La Marca are excluded from the GLP-1 discount program due to specific medical conditions. This program, which started in July as a temporary measure, aims to help those who cannot access GLP-1 medications through traditional Medicare Part D plans, which typically involve high copays.

The Medicare GLP-1 Bridge program is designed for eligible patients with a body mass index (BMI) of 35 or higher, or those with a BMI of 27 to 34 who also have certain health conditions. However, the fine print specifies that only individuals using these medications solely for weight loss will benefit from the reduced price. Those with qualifying medical conditions, such as Type 2 diabetes or moderate to severe obstructive sleep apnea, must revert to their Medicare Part D plans, often facing copays ranging from $200 to $600.

Juliette Cubanski, director of the Program on Medicare Policy at KFF, explained that the program targets individuals who cannot obtain GLP-1 coverage through Part D but would benefit from the drugs for weight loss. The program's expenses will depend on enrollment numbers, with estimates suggesting costs could reach up to $10 billion if a significant portion of eligible beneficiaries utilize the program.

Despite initial positive feedback regarding the pilot's execution, patients like La Marca remain in a challenging position. Many already struggle with the complexities of prior authorization and step therapy, often leading to prolonged periods of navigating through cheaper alternatives before they can access necessary treatments.

Dr. Taylor Lacy, a primary care physician, criticized the program for leaving patients with severe medical needs without adequate support. For La Marca, the denial of his prescription due to his sleep apnea diagnosis is particularly disheartening, as he views GLP-1 medications as his last hope for improving his health after numerous failed attempts with diets and exercise.

As he contemplates the bureaucratic hurdles and his ongoing health battle, La Marca expressed his determination to seek a resolution. "This is now my quest, because it’s my only chance to improve my health. It’s the only thing left. I’ve tried everything," he lamented.

Source: kffhealthnews.org